Australia's First
CJC-1295 & Ipamorelin
Subcutaneous Pen



What is CJC-1295 (no DAC) + Ipamorelin?

CJC-1295 (no DAC) and Ipamorelin; in a sterile compounded subcutaneous pen for precision micro-dosing.

This dual-peptide system supports growth hormone release, cellular recovery, and metabolic balance, promoting deep sleep, lean mass retention, and connective-tissue repair.

Each pen is compounded by a licensed Australian pharmacy and dispensed under prescription for clinician-supervised use only.

What CJC-1295 (no DAC) + Ipamorelin Are Being Studied For?

Both peptides stimulate pulsatile growth hormone (GH) secretion but via distinct mechanisms, making their combination clinically complementary.

CJC-1295 (no DAC)
A synthetic growth hormone–releasing hormone (GHRH) analogue that binds to pituitary GHRH receptors.
Mechanism: Increases amplitude of natural GH pulses without continuous receptor stimulation.
Physiological Role: Enhances protein synthesis, tissue repair, and fat metabolism.

Ipamorelin
A selective growth hormone secretagogue (GHS) acting at the ghrelin (GHS-R1a) receptor.
Mechanism: Promotes GH release through ghrelin-mimetic pathways with minimal cortisol or prolactin elevation.
Physiological Role: Improves recovery, sleep quality, and lean body composition.

Together they produce additive GH stimulation while maintaining physiologic rhythm; avoiding receptor fatigue associated with longer-acting analogues (DAC variants).

How It's Dispensed?

When prescribed, the CJC-1295 + Ipamorelin formulation is compounded by an Australian-registered pharmacy and dispensed under pharmacist supervision.

Concentration: CJC-1295 (2 mg/mL) + Ipamorelin (2 mg/mL)
Volume: 3 mL pre-filled subcutaneous pens
Preservative system: Formulated in accordance with pharmacy sterility and stability standards
Temperature control: Shipped in insulated packaging with cold packs to maintain integrity during transport

Storage & Handling

Keep refrigerated as directed by the dispensing pharmacy.
Do not freeze or expose to excessive heat.
If ice packs melt during transit, product integrity remains unaffected within the advised shipping window.
Always follow the storage and handling guidance supplied with your prescription.

Usage & Administration

Administration technique, dose volume, and frequency are determined individually by the prescribing clinician.

Follow all instructions printed on the pharmacy label. Do not self-administer unless you have received appropriate training and clinical clearance.

Typical practitioner-directed use may include:
Route: Subcutaneous injection via pre-filled CJC-1295 (no DAC) + Ipamorelin pen.
Injection site: Lower abdomen or outer thigh for systemic effect.
Pattern: Twice-daily dosing (one injection in the morning and one injection in the evening) to align with natural growth hormone; or as directed by the clinician.
Cycle: Typically administered daily in the AM and PM; fasted, unless otherwise adjusted by the prescriber.
Technique: Clean the skin with an alcohol swab, dial the pen to the prescribed unit setting, administer the dose as instructed, and dispose of the needle safely after each injection.
Rotation: Rotate injection sites between left and right sides of the lower abdomen or thighs to minimise irritation and support consistent absorption.

All dosing parameters (including unit setting, AM/PM timing, weekly cycle structure, and total course duration) are determined by the prescribing clinician based on individual goals, tolerability, and the overall treatment plan.

Safety & Precautions

Schedule 4 (Prescription-Only Medicines) must be prescribed and supervised by a registered healthcare professional.
Disclose all medical conditions, allergies, and concurrent medications before treatment.
Not recommended during pregnancy or breastfeeding unless specifically approved by a clinician.
Report any irritation or unexpected response to your prescriber or pharmacist.
Always store and administer as directed by the dispensing pharmacy.

Research Context

CJC-1295 (no DAC) and Ipamorelin remain subjects of ongoing investigation in the fields of endocrinology and regenerative peptide therapy.

Existing clinical and pre-clinical studies indicate that these peptides can stimulate endogenous growth hormone release through complementary mechanisms — CJC-1295 via GHRH receptor activation and Ipamorelin via selective ghrelin receptor (GHS-R1a) binding — without significantly altering cortisol or prolactin levels.

Preliminary findings suggest potential benefits for lean muscle preservation, metabolic function, and recovery optimisation; however, robust human data remain limited, and long-term safety outcomes are not yet established.

All prescribing in Australia is conducted under compounded, off-label frameworks, with use restricted to qualified medical practitioners operating within appropriate clinical governance.

Disclaimer

Educational content only; not medical advice.

CJC-1295 and Ipamorelin compounded preparations are not registered with the Therapeutic Goods Administration (TGA).

No claims of efficacy or therapeutic outcome are made.

All use requires individual consultation and prescription by a registered clinician.

Mobile IV Drip

CJC-1295 and Ipamorelin Australia

Prescription CJC-1295 and Ipamorelin

Australian Compounded Peptides

Australian Compounded Prescription Peptides

CJC-1295 no DAC and Ipamorelin Pen

CJC-1295 and Ipamorelin Subcutaneous Pen

Growth Hormone Support Peptides

Recovery and Sleep Support Peptides

Body Composition Support Peptides

Regenerate CJC-1295 and Ipamorelin

Inject+ Disclaimer

By continuing, you acknowledge and agree to the following terms and conditions of ExclusIV by Mobile IV Drip:

1. Elective Wellness Services
All IV infusions and subcutaneous products offered through Mobile IV Drip are elective wellness services. They are not prescribed or promoted as medically necessary treatments and are designed to support general wellness and vitality.

2. No Public Advertising
The information displayed in this section is provided privately on request and does not constitute public advertising.

3. No Medical or Therapeutic Claims
No statements here should be interpreted as claims of therapeutic benefit. Services and compounded formulations are not a substitute for professional medical advice, prescribed medication, or conventional treatment.

4. Practitioner Review Required
Before any compounded or prescription-only product is supplied, clients are required to complete medical intake and be reviewed by an authorised prescriber and/or nurse practitioner, and obtain a prescription where required.

5. Pricing
Pricing shown is indicative only and may change following clinical assessment, prescription requirements, or compounding variables. Final costs are confirmed after prescriber approval.

6. Voluntary Request
You confirm you are voluntarily requesting this information for personal education, and that access does not guarantee suitability for every option listed.

7. Privacy
Any information you provide may be used to communicate about consultations, prescriptions or updates, with opt-out available.

By selecting “I want ExclusIV access”, you confirm you have read and understood the above.